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Post-stroke systemic injections of insulin-like growth factor-1 (IGF-1) exert
neuroprotective effects in rats. In the current study, we aimed to test the efficacy
of IGF-1 neuroprotection in aged rats (24–25 months old) and to compare the results
with adult rats (6–7 months old). Furthermore, we addressed putative differences in
microglial responses to IGF-1 in adult and aged rats. Rats were subjected to ischemic
stroke while they were conscious by infusing endothelin-1 (Et-1) through a guide cannula
that was implemented in the vicinity of the middle cerebral artery (MCA). Rats were
given subcutaneous injections of IGF-1 (1 mg/kg) at 30 min and 120 min after the insult.
Post-stroke IGF-1 treatment reduced the infarct size by 34% and 38% in aged and adult
rats, respectively. The IGF-1 treated adult rats also showed significant improvement in
sensorimotor function following stroke, while this function was not significantly affected
in aged rats. Furthermore, aged rats displayed exaggerated activation of microglia in
the ischemic hemisphere. Significant reduction of microglial activation by IGF-1 was
only detected at specific regions in the ipsilateral hemisphere of adult rats. We show
that IGF-1 reduced infarct size in aged rats with an ischemic stroke. It remains to be
established, however, whether the age-related changes in microglial function affect the
improvement in behavioral outcomes.
Keywords: aging, IGF-1, stroke, microglia, neuroprotection
INTRODUCTION
Ischemic stroke is one of the most common causes of death and disability (Katan and Luft, 2018).
Thrombolytic therapy with recombinant tissue plasminogen activator is still the most effective
therapy for ischemic stroke (Lees et al., 2016; Alberts, 2017). However, many patients are not
eligible for this therapy due to the narrow therapeutic window (Lees et al., 2016; Alberts, 2017).
In stroke patients, serum levels of insulin-like growth factor-1 (IGF-1) correlate positively with
clinical outcome (Åberg et al., 2011, 2018; De Smedt et al., 2011; Saber et al., 2017) suggesting
that IGF-1 may exert neuroprotective effects. IGF-1 is a polypeptide hormone that is involved
in neonatal and postnatal development (Agrogiannis et al., 2014; Hellström et al., 2016; de Jong
et al., 2017), but also acts as a survival factor for neurons in vitro (Ueno et al., 2013) and in vivo
(Wine et al., 2009).
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Moreover, post-stroke treatment with systemically injected
IGF-1 induced neuroprotection in several rat models for
ischemic stroke (Rizk et al., 2007; De Geyter et al., 2013, 2016;
Bake et al., 2014). These observations indicate that IGF-1 may be
effectively used as a neuroprotective agent in patients.
Many preclinical studies successfully identified
neuroprotective drugs against ischemic stroke, but these
drugs failed to exert significant effects in the clinic (Green,
2008; Veltkamp and Gill, 2016). One of the recommendations
of the Stroke Therapy Academic Industry Roundtable (STAIR;
Fisher et al., 2009) to facilitate translation to the clinic, is to
include comorbidity factors such as aging in preclinical studies.
Indeed, the incidence of stroke is higher in the elderly (Béjot
et al., 2016). Therefore, we tested whether IGF-1 treatment is
neuroprotective in aged rats and compared the results to the
efficacy of IGF-1 in adult rats. Preliminary experiments in our
laboratory revealed that neuroprotection by IGF-1 in rats with
ischemic stroke is accompanied by microglial changes and a
decrease in neuroinflammation. Since age correlates with an
exaggerated activational state of microglia (Godbout et al., 2005;
Norden and Godbout, 2013), we addressed the effects of IGF-1
on microglial activation.
MATERIALS AND METHODS
Male albino Wistar Han rats were obtained from Charles River
Laboratories (Germany). After transport, animals remained in
the animal facility for several months under a 12-h light/dark
cycle with ad libitum food and water. The animals were
handled in accordance with the National Guidelines on Animal
Experimentation and the study was approved by the Ethical
Committee for Animal Experimentation of Vrije Universiteit
Brussel (VUB, project number: 14-278-2).
Surgical Operation and Induction of Stroke
Adult rats (6–7 months) were anesthetized using 1.5–3.5%
isoflurane. Since aged rats (24–25 months old) were more
sensitive to isoflurane gas anesthesia, they were anesthetized
using 1.5–2% isoflurane. Next, the rats were fixed on a
stereotactic frame and injected subcutaneously (SC) with
5 mg/kg ketoprofen. A midline incision was applied in the
skull and then a burr hole was drilled carefully. Thereafter,
a guide cannula (C317G/SPC, Invivo1, Roanoke, VA, USA)
was inserted in the vicinity of middle cerebral artery (MCA).
The coordinates for the guide cannula implementation were
determined according to the Paxinos and Watson atlas (Paxinos
and Watson, 2008) and the weight of the rats. The optimal
coordinates for guide cannula implementation for rats weighing
275–300 g are: +0.9 mm anterior/posterior from Bregma, +5 mm
lateral from Bregma and 2.8 mm ventral from dura (De Geyter
et al., 2013, 2016; Zgavc et al., 2013). Since adult and aged rats
weremore than 450 g, the coordinates for guide cannula insertion
were optimized and verified histologically afterward. For both
adult and aged rats the following coordinates for guide cannula
insertion were applied: +1 mm anterior/posterior from Bregma,
+5.4mm lateral from Bregma and 3mm ventral from dura. Adult
rats were left to recover for 1 day after surgery. Since aged rats
appeared to be less active after surgery and more vulnerable,
they were allowed to recover for 2 days. After recovery, the
internal cannula (C317I/SPC, Invivo1, Roanoke, VA, USA) was
connected to the guide cannula and stroke induction was induced
in freely moving rats by infusing endothelin-1 (Et-1; Sigma,
St. Louis, MO, USA). Et-1 is a potent vasoconstrictor which
induces a 75% reduction of cerebral blood flow during 30 min
after which the blood flow gradually returns to basal levels
(Bogaert et al., 2000). We conducted a dose-ranging study and
found that infusion of 6µl Ringer’s solution containing 260 pmol
or 120 pmol Et-1 induced comparable cerebral infarcts in adult
and aged rats, respectively. The sham rats were infused with
Ringer’s solution only. All rats were euthanized 24 h after
induction of stroke.
IGF-1 Injection
Our group established before that SC administration of 1 mg/kg
recombinant human (rh) IGF-1 (Ipsen NV, Merelbeke, Belgium)
at 30 min after stroke reduced infarct volume by 27%, but
had no effect on sensorimotor function (De Geyter et al.,
2013). It was also shown that increasing the dose to 3 mg/kg
had no additional effect on infarct volume and did not
ameliorate neurological deficits (De Geyter et al., 2013). In
contrast, SC administration of IGF-1 (1 mg/kg) at 30 min and
120 min decreased the infarct volume by 32% and improved
the behavioral outcome (De Geyter et al., 2013). Additional
injections at 4 h and 6 h after the stroke did not lead to
further ameliorations (De Geyter et al., 2013). In the current
study, rats were coded and randomly assigned to vehicle or
treatment groups and SC injected with a 0.4 ml solution
of vehicle or IGF-1 at 30 and 120 min after the insult.
Group sizes and animals excluded from the analysis are listed
in Table 1.
Sensorimotor Function
The sensory and motor functions were assessed in a blinded
manner using the Neurological Deficit Score (NDS) described
by Garcia et al. (1995). The NDS test was applied approximately
30 min before surgery and 24 h after induction of stroke
assessing six parameters: spontaneous movement, outstretching
of the forepaws, climbing, symmetrical movement of forelimb,
response to vibrissae touch and body proprioception. The NDS
which ranges from a minimum score of 3 to a maximum score
of 18, is inversely associated with sensorimotor impairment.
The NDS scores before surgery were 18 in both adult
and aged rats.
Measurement of Infarct Volume
After performing the behavioral tests, rats were euthanized
by intraperitoneal injection with an overdose of sodium
pentobarbital. Transcardial perfusion with saline for 5 min
was followed by perfusion with 4% paraformaldehyde for
5 min. Next, brains were collected and post-fixed in 4%
paraformaldehyde. After post-fixation for at least 3 days, brains
were cut into 50 µm coronal sections using a vibratome
(Leica VTS1000, Bensheim, Germany), and stored at 4◦C in
phosphate buffered saline (PBS) containing 0.01% sodium azide.
Assessment of infarct volume was done by mounting every
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TABLE 1 | Summary of the mortality at different stages of the experiment and
the reasons for exclusion with respect to estimation of infarct size and NDS.
Adult Aged
Adult Aged Vehicle IGF-1 Vehicle IGF-1
• Group size 7 9 9 12
• Excluded due to
wrong guide cannula
position
1 2 1 1






• Excluded due to lack
of good sections to
stain with Cresyl Violet
2
• Died naturally before
surgery
4
• Died during surgical
procedure
2
• Died during stroke
induction
5 8
fourth section on gelatin-coated slides. The slides were stained
with 0.5% cresyl violet acetate and the infarcted surface areas
(Figure 1A) were measured on digitized images using ImageJ
software (NIH, v 1.43). The infarct volume was estimated using
the following equation: v = d × Σa, where (v) is the infarct
volume (mm3), (d) is the distance between two consecutive brain
sections and (a) is the surface area of infarct size as described by
Avendaño et al. (1995). Infarct volume was corrected for edema
using the following equation:
Infarct volume× (volume of contralateral hemisphere/volume
of ipsilateral hemisphere)
Immunohistochemistry
Two or three coronal brain sections (50 µm) were taken to
assess the microglia activation using ionized calcium binding
adaptor molecule-1 (Iba-1) staining. The brain sections were
selected as follows: one brain section near 0.90 mm anterior to
Bregma, one brain section near 0.26 mm posterior to Bregma
and one brain section in the middle of the aforementioned
coordinates. After subsequent incubation in 3% H2O2 in water
(30 min), 0.1% Triton X-100 in water (15 min) and 20%
normal goat serum in PBS (30 min), brain sections were stained
overnight with rabbit anti-Iba-1 (1:1,000 dilution in 20% normal
goat serum in PBS; Wako, Japan) at 4◦C. Next, brain slices
were incubated with horseradish peroxidase-conjugated donkey
anti-rabbit IgG (NA934V, GE Healthcare, UK; 1:100 dilution in
20% normal goat serum in PBS) for 4 h at room temperature
and binding of this secondary antibody was visualized using the
diaminobenzidine substrate chromogen kit (Dako Cytomation,
FIGURE 1 | Effect of post-stroke IGF-1 treatment on infarct volume and
sensorimotor function in adult and aged rats. (A) Representative micrographs
of infarct regions in treatment and vehicle groups of both adult and aged rats.
Panels (B,C) show the effect of IGF-1 on the infarct volume in adult and aged
rats, respectively. The effect of IGF-1 treatment on sensorimotor function in
adult and aged rats is represented in panels (D,E), respectively.
Vehicle-treated adults (n = 6), IGF-1 treated adults (n = 5 for infarct and
n = 7 for NDS), vehicle-treated aged rats (n = 7) and IGF-1 treated aged rats
(n = 8). Significance ∗P < 0.05; ∗∗P < 0.01. ns: not significant.
Glostrup, Denmark). Negative controls were incubated in
normal goat serum without the primary antibody. The brain
slices were cover-slipped using DPX mounting medium and
scanned afterward with Aperio CS2 scanner (Leica, Belgium).
The brain sections that are stained with Iba-1 in adult and
aged rats are shown in Figure 2. The regions of interests
(ROI’s; 0.25 mm2 each) to study microglial activation in the
ipsilateral hemisphere were selected using the ruler tool in Aperio
ImageScope software (Version 12.1.0.5029, Leica, Belgium). The
ROI’s were selected in the infarcted regions (II, III and IV
in the striatum and VI and VII in the cortex), at the border
of the infarct (I and V) or outside the infarct (region VIII
in the corpus callosum) using adult vehicle-treated rats. A
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FIGURE 2 | Morphology of microglia in contralateral and ipsilateral
hemisphere of IGF-1 treated adult and aged rats. The upper and lower left
micrographs show the surveying microglia in the contralateral hemisphere of
adult and aged rats, respectively. The activated microglia are shown in the
upper right micrograph which shows two morphological phenotypes of
activated microglia in the striatum of the ipsilateral hemisphere of adult rats:
ameboid microglia (arrow) and activated ramified microglia (arrowhead). The
clusters of activated microglia in the infarcted striatum of aged rats are
represented in the lower right micrograph.
horizontal line was annotated on top of the striatum of the two
hemispheres and this line was used as a reference to determine
the position of the ROI’s on the Y-axis (Figure 3A). Then, a
parallel line was drawn and regions I and III were annotated
along this line at the edges of the striatum. Subsequently,
regions II, IV and VI were annotated by taking region III
as a reference and region VII was selected based on region
VI. A vertical line crossing the top of the corpus callosum in
the ipsilateral hemisphere was used as a reference to annotate
region VIII in the corpus callosum. Region V was selected based
on region VIII as indicated in Figure 3A. After annotating
the ROI’s, microglial activation was assessed by quantifying
the number of Iba-1 positive pixels which were analyzed by
an Aperio Positive Pixel Count v9 algorithm. Three categories
of pixels (weak positive, positive and strongly positive) were
generated, summed and quantified as the number of positive
pixels/0.25 mm2.
Statistics
All data are presented as mean ± SD. Statistical significance for
the infarct volume and Iba-1 positive pixels between vehicle- and
IGF-1-treated groups were analyzed using the unpaired student’s
t-test. The NDS score was analyzed by the Mann–Whitney test.
The results were considered significant when P< 0.05. Statistical
analysis was performed using GraphPad Prism 7 (version 7.0a for
MacOS, GraphPad Software, La Jolla, CA, USA).
RESULTS
Effect of Post-stroke IGF-1 Administration
on Infarct Size and Sensorimotor Function
Subcutaneous injections of IGF-1 at 30 min and 120 min
after the insult resulted in a significant reduction of
infarct volume by 38% and 34% in adult and aged rats,
respectively (Figures 1A–C). A concomitant improvement in
sensorimotor behavior was observed in both adult and aged
rats, but this effect only reached significance in adult rats
(Figures 1D,E).
Modulation of Microglial Activation by
IGF-1 in Adult and Aged Rats
Although microglia and macrophages share morphological
features and express similar markers including Iba-1, we assessed
the activation of microglia by Iba-1 staining as macrophages do
not infiltrate the brain within 24 h of stroke onset (Schilling et al.,
2003). The surveying microglia are found in the contralateral
hemisphere, while the activated microglia are predominantly
abundant in the ipsilateral hemisphere (Figure 2). The activated
microglia in adult rats were morphologically classified into
activated ramified and ameboid microglia. The former exhibit a
dense cell body and thick ramifications (Figure 2, arrowhead),
while the latter are characterized by a round-shaped and
dense cell body, and phagocytic activity (Figure 2, arrow).
Furthermore, Figure 2 reveals that surveying microglia in the
contralateral hemisphere of aged rats exhibited a different
morphological phenotype from that of adult rats. Surveying
microglia in the striatum of aged rats had small or no
ramifications compared to the surveying microglia in adult rats
(Figure 2). On the other hand, aged rats displayed aggregates of
activated microglia in the ipsilateral hemisphere of rats with an
ischemic stroke (Figure 2).
To address the effect of IGF-1 treatment on microglial
activation in the ipsilateral hemisphere, we analyzed Iba-1
positive pixels in ROI’s that were selected from the infarcted
and non-infarcted regions in the vehicle-treated adult rats. It
appeared that IGF-1 decreased the number of Iba-1 positive
pixels at the border of infarction in the striatal regions I and
V of adult rats, but was without effect in other regions in the
striatum, cortex and corpus callosum (II, III, IV, VI, VII andVIII;
see Figures 3B–E). In contrast to adult rats, aged rats did not
show a reduction in positive pixels in the striatal regions I and
V (Figure 3C). Furthermore, the microglial activation in other
regions was also not affected by IGF-1 treatment of aged rats
(Figures 3B–E).
DISCUSSION
IGF-1 has been used extensively as a potent neuroprotective
agent in several animal models for ischemic stroke (Guan et al.,
2001; De Geyter et al., 2013; Bake et al., 2014). However,
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FIGURE 3 | Effect of IGF-1 on the activation of microglia in adult and aged rats. (A) Illustration of the positions of the ROI’s in the ipsilateral hemisphere of an IGF-1
treated adult rat stained with Iba-1. (B) Representative micrographs of the effect of IGF-1 on the activation of microglia in regions I, III and V of the striatum.
Panels (C–E) display the differences in Iba-1 positive pixels (number of pixels/0.25 mm2) in different regions in the striatum, cortex and corpus callosum in adult and
aged rats. Scale bar of the micrographs in (B) is 50 µm. The number of adult rats per each group: All regions for vehicle and IGF-1 treatments (n = 5), except for
vehicle region VI and IGF-1 region VII (n = 4). The number of aged rats per each group: Vehicle and IGF-1 regions I, II, III, IV and V (n = 7), vehicle region VI (n = 4),
vehicle and IGF-1 region VII, IGF-1 region VI and vehicle region VIII (n = 6) and IGF-1 region VIII (n = 5). Significance ∗P < 0.05.
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comorbidities may affect the treatment efficacy in preclinical
models, e.g., the neuroprotective effect of IGF-1 following
ischemic stroke was impaired in hypertensive rats, compared
to normotensive rats (De Geyter et al., 2013). It has also been
shown that post-stroke treatment with fluoxetine, a selective
serotonin reuptake inhibitor, was neuroprotective and improved
the sensorimotor function in adult rats (Lim et al., 2009),
while fluoxetine treatment following stroke in aged rats did
not have an effect on infarct volume and behavioral outcome
(Zhao et al., 2005). Also, the beneficial effects of leukemia
inhibitory factor (Davis et al., 2019) and apocynin (Kelly et al.,
2009) which were observed in young adult rats were absent
in aged rats.
Age is one of the most prominent risk factors for stroke
and can be modeled in rodents. We addressed the potential
neuroprotective effects of systemic administration of IGF-1 in
aged Wistar Han rats using the Et-1 model for the induction
of ischemic stroke in conscious animals. We previously showed,
using this model, that SC injection of IGF-1 following stroke
reduced infarct volume by 32% in 3-month-old rats and
improved the NDS score (De Geyter et al., 2013). In the
current study, we show similar results in 6–7 month-old
rats in which IGF-1 reduced infarct volume by 38% and
compared the neuroprotective effects of IGF-1 in these rats
with the effects in 24–25-month-old rats (Figures 1A–C). To
our knowledge, we are the first to demonstrate that post-stroke
systemic administration of IGF-1 reduces infarct size in aged
rats (Figures 1A,C). Although IGF-1 treatment significantly
improved the NDS following ischemic stroke in adult rats
(Figure 1D), this score was not significantly improved in aged
rats (Figure 1E). The smaller effect on sensorimotor behavior
may be due to the finding of DiNapoli et al. (2008), that
there is a delay in recovery after ischemic stroke in older
animals or may be related to the exaggerated activation of
microglia in the ipsilateral hemisphere (Figure 2). Another
explanation could be that in aged rats a further reduction
in infarct volume may be needed to achieve a significant
improvement in sensorimotor functions. The latter explanation
is in line with our observation that a 32% reduction in infarct
size coincides with an improvement in behavioral outcome,
while a 27% reduction was without effect (De Geyter et al.,
2013). Moreover, future studies, with larger sample sizes, are
recommended to establish the effect of IGF-1 at different time
points beyond 24 h of stroke induction, especially with respect
to possible short-term confounding effects of the anesthesia
before the induction of stroke. Alternatively, adjustments of
the dose of IGF-1 may be required to significantly augment
sensorimotor behavior in aged rats. Although the NDS test is
easy to conduct on animals, it is only suitable for testing during
the acute phase of ischemic stroke, as the assessed neurological
deficits disappear within a few days after stroke (Balkaya et al.,
2018). Hence, long-term studies using alternative behavioral tests
are warranted.
Although one of the advantages of the Et-1 model is that
stroke is induced in conscious animals in the absence of
neuroprotective anesthetics, the possibility remains that the
outcome will be influenced by the long-term effects of anesthesia.
In addition, these long-term effects may be different in aged rats
compared to adult rats, also, because of the differences in doses of
isoflurane that the animals had been exposed to. In future studies,
these differences can beminimized by allowing the rats to recover
for more than 2 days after surgery. Nevertheless, a limitation of
our study with respect to the comparison between adult and aged
rats is that aged rats were more vulnerable than adult rats and
required adaptations in the procedures for surgery and induction
of stroke by Et-1.
To assess whether activation of microglia is instrumental
to neuroprotection, microglia were stained with Iba-1. The
neuroprotective effect of IGF-1 in adult rats following ischemic
stroke was paralleled by a decrease in Iba-1 positive pixels in
regions I and V at the border of the infarct (Figures 3A–C).
The reduction on microglial activation in regions I and V
which are, at least partially, salvaged by IGF-1 treatment in
adult rats (Figure 1A) is to be expected, but the absence of
this reduction in aged rats is remarkable. It could be that
alleviating the activation of microglia at the border or in
the vicinity of the infarcted regions may be necessary for
the improvement in functional outcome. Our observation that
IGF-1 does not affect Iba-1-staining in aged rats could be
due to age-dependent alterations in the activational state of
microglia. Indeed, surveying microglia in aged rats showed
relatively small or no protrusions and dense soma in the
contralateral hemisphere (Figure 2). This is in agreement with
another study that demonstrated microglia in aged mice have
shorter ramifications, enlarged cell body and non-homogenous
distribution (Damani et al., 2011; Hefendehl et al., 2014).
Moreover, it has been shown that microglia in the aged brain
are primed (or reactive), have pro-inflammatory profile and
are characterized by an increased level of activation markers
including CD86, major histocompatibility complex, toll-like
receptors (Frank et al., 2006; Letiembre et al., 2007; Norden and
Godbout, 2013). It has also been shown that aged mice display
an increased and prolonged secretion of pro-inflammatory
cytokines in response to lipopolysaccharide, compared to adult
mice (Norden and Godbout, 2013). Our finding that aged rats
have clusters of activated microglia in the ipsilateral hemisphere
of the ischemic brain (Figure 2), is also consistent with
these observations in the literature. Since it is not possible to
characterize the different types of microglia in aged rats using
2D-images (Figure 2), the use of confocal stack images for 3D
cell reconstruction employed by Wagner et al. (2013), could be
useful in future studies on the role of glial cells in neuroprotection
in aged rats.
Another limitation of the Et-1 model is that an invasive
method is required to infuse Et-1 next to the MCA. Indeed, in
aged rats, the insertion of the guide cannula evoked activation
of microglia in the ipsilateral hemisphere as assessed by Iba-1
staining in sham rats. Although establishing the effects of IGF-1
on these artifacts in sham rats would be worthwhile, the effects
of IGF-1 on microglial activation in regions I and V shown in
Figure 3, were located outside the region that was affected by the
insertion of the guide cannula. Although reactive microglia may
adversely affect the efficacy of treatment due to their exaggerated
inflammatory responses, our results suggest that the increase in
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reactive microglia following stroke did not affect the reduction in
infarct size in aged rats.
Taken together, our results clearly demonstrate that IGF-1
exerts a promising neuroprotective effect in aged rats when it
comes to the reduction in infarct size. However, it remains to
be established whether age in stroke patients could influence
the clinical outcome after IGF-1 treatment. Future studies are
warranted to shed light on the underlying mechanisms of
IGF-1 neuroprotection in ischemic aged rats and the role of
the microglia.
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